FIRST LIGHT DIAGNOSTICS

Company Overview
Marketing Materials
Data Room
Management Bios
Videos
News & Articles
Contact Us
Company Overview
COMPANY OVERVIEW
 

First Light’s mission is to dramatically accelerate the “time to result” for earlier detection of infectious disease pathogens that cause hospital-associated infections. Our goal is to provide clinicians with life-saving antimicrobial susceptibility test results in hours instead of days. Leveraging the highly differentiated MultiPath™ technology platform, we strive to save lives of patients who are suffering from life-threatening infections by enabling more rapid treatment decisions.

Our Technology

The MultiPath™ technology offers a powerful approach for rapid and sensitive detection of diagnostic markers directly in complex sample matrices. The combination of highly sensitive non-magnified digital imaging coupled with specific targeting provides the ideal platform for high-performance, highly sensitive testing covering a broad range of diagnostic and infectious disease applications. Our technology provides true multiplexing capability, allowing both flexible and ultrasensitive detection of bacteria, fungi, viruses, toxins, biomarkers, and diagnostically important human cells. The same technology can be applied to rapidly determine differential growth patterns of selected pathogens under the presences of antibiotics, making it an ideal tool for determining susceptibility of multi-drug resistant bacterial infections.

Deal Size
$4,500,000
Min Investment
$1,000,000
Industry
Venture Capital
Type of Investment
1031 Exchange
Location
Chelmsford, MA
Contact Us

Marketing Materials
Data Room
Management Bios
MANAGEMENT BIOS
James Franklin
CEO
Connie Barabosa
CFO
Videos
VIDEOS
Leading Clinicians Discuss Antibiotic Resistance
June 21, 2019
The MultiPath System, By First Light Diagnostics
June 21, 2019
First Light MultiPath Analyzer
September 6, 2018
News & Articles
NEWS & ARTICLES
First Light Diagnostics Announces Closing of a $4.5 million Debt Financing

Additional funds to support the company’s diagnostic platform initiatives Chelmsford, MA – (June 19, 2019) – First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis and treatment of life-threatening, antibiotic-resistant infections, today announced the closing of a $4.5 million debt financing. This includes a Lease Line with CSC…

First Light Diagnostics to Showcase MultiPath™ Platform at ASM Microbe 2019

CHELMSFORD, Mass., June 6, 2019 (Newswire.com) –  First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced its participation at the American Society for Microbiology’s ASM Microbe 2019 Event in San Francisco, California, from June 20-24. First Light Diagnostics will be exhibiting in the Innovation Zone, the newest addition…

First Light Diagnostics Welcomes New Vice President of Quality Assurance and Regulatory Affairs

Chelmsford, MA, April 10, 2019 (Newswire.com) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the hiring of Andrew Connerty as its Vice President of Quality Assurance and Regulatory Affairs. Andrew Connerty brings more than 25 years of Quality Systems management expertise at…

First Light Diagnostics Recognized by Frost & Sullivan as Technology Innovation Leader

First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced it has been recognized by Frost & Sullivan for best practices in Technology Innovation in the Rapid Diagnostics Industry. Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that…

Dr. Stephen Brecher Joins First Light Diagnostics Clinical Advisory Board

Chelmsford, MA (March 13th, 2019) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Dr. Stephen Brecher to the company’s world-class, international Clinical Advisory Board. “Stephen is an internationally recognized expert for his work with C. difficile infections and…

Contact Us
CONTACT US
OFFICE ADDRESS:
2 Omni Way, Chelmsford, MA 01824

P: 781-271-0112
E: [email protected]

LinkedIn Profile    Twitter Profile    Facebook Profile